POS1542 THE PSORIATIC ARTHRITIS IMPACT OF DISEASE (PSAID-12) QUESTIONNAIRE IS VALID IN ARABIC AND STRONGLY LINKED TO DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN ARAB-SPEAKING COUNTRIES: AN ARLAR INITIATIVE
Authors: N. Ziade, N. Abbas, I. Hmamouchi, L. Kibbi, A. Maroof, B. Zorkany, N. A. Al-Ani, A. Ridha, N. Ihsan, F. Isho Gorial, N. Al Chama, C. Haouichet, F. Alnaimat, S. Hannawi, S. Atawina, H. Halabi, M. Mashaleh, L. Aljazwi, A. Abogamal, L. Ayoub, E. Bouajina, R. Bahiri, S. Saad, M. Sabkar, K. Aouad, L. Gossec
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The Psoriatic Arthritis Impact of Disease (PsAID) is a patient-reported questionnaire assessing multiple domains in patients with psoriatic arthritis (PsA), developed under the aegis of EULAR, and recommended by OMERACT and GRAPPA. To be usable in different contexts, translations and cross-cultural validations are necessary. Arabic is the sixth most-spoken language in the world; however, many patient-reported outcomes are not available in Arabic. <h3>Objectives</h3> To translate, culturally adapt and validate the PsAID-12 questionnaire in Arabic, to study its psychometric properties, and to evaluate its association with the demographic and disease characteristics of PsA patients. <h3>Methods</h3> This multicentric multinational study was conducted by the Arab League of Associations of Rheumatology (ArLAR) research group (ARCH). Validated methodologies were applied. (A) Phase 1: Translation of PsAID-12 into Arabic, including a double translation, synthesis by a steering committee, back-translation, and cognitive debriefing with feasibility and timing assessment with a sample of patients with PsA in four countries. (B) Validation phase: Cross-sectional study, with a longitudinal part for reliability testing, conducted in thirteen Arab countries. Patients were consecutive adult patients, diagnosed with PsA (rheumatologist opinion + CASPAR criteria), literate, and agreeing to participate. Data collected: (1) From the patient: PsAID-12 in Arabic, demographic and disease information, Health Assessment Questionnaire (HAQ), Patient Global Assessment for pain and disease activity (PGA), Fibromyalgia Rapid Screening Tool (FiRST) and Patient Health Questionnaire (PHQ4). (2) From the rheumatologist: Disease Activity in Psoriatic Arthritis (DAPSA) score. Psychometric properties of the PsAID-12 were investigated: internal consistency (Cronbach α), construct validity (Spearman correlation with DAPSA, HAQ, PGA, FiRST, PHQ4), and test-retest reliability (intraclass correlation coefficients (ICCs) and Cohen kappa at one week). (C) Factors associated with high PsAID-12 total score (defined as &gt;= 4) were explored using multivariable binary logistic regression. <h3>References:</h3> [1] Translation phase: a culturally adapted questionnaire was obtained, with minor rephrasing and addition of examples for better clarity. Feasibility was scored at 2/10 (SD 1.7) (10 being the most difficult) and the time needed to complete the questionnaire was 4.16 minutes. [2] Validation phase: in 554 patients from 13 countries, mean age was 45 years [SD 13], 57% were females. The mean PsAID score was 3.86 (SD 2.33). Internal consistency was excellent (Cronbach α = 0.95). The correlation coefficients with other measures were moderate to strong (range, 0.63 to 0.78 (Figure 1). Test-retest reliability (N=138 patients) was excellent (ICC 0.95 (95%CI 0.86;0.93) and agreement between the first and second measurements was substantial (Cohen kappa 0.797). [3] In the multivariable analysis, factors associated with a higher PsAID were DAPSA, FiRST, and PHQ4 (after adjustment for axial involvement, education, gender, and CRP). <h3>Conclusion</h3> The Arabic PsAID is a consistent, reliable, and feasible measure in patients with PsA. The correlation with other PsA-related measures appears similar to the correlation noted in other cultures and languages. The PsAID appears to be a stable measure of impact across cultures. These results comfort the recommendation to use the PsAID for clinical practice and research purposes. <h3>Acknowledgements</h3> Dr Suad Hashad, Ms Arlyn Lim Acenas. <h3>Disclosure of Interests</h3> None Declared.